Snapshot from Sep 12, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

FDA accepts IND for NBI-1117567

Analysis based on 7 articles · First reported Aug 26, 2026 · Last updated Aug 26, 2026

Sentiment
30
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The IND acceptance triggers a US$10 million milestone payment to Nxera, providing immediate revenue and validating its NxWave platform. Positive regulatory progress for NBI-1117567 may boost investor sentiment for both Nxera and Neurocrine, though the drug is still in early-stage development.

Pharmaceuticals Biotechnology

On 26 August 2026, Nxera Pharma announced that its partner Neurocrine Biosciences received IND Acceptance from the U.S. United States — Food and Drug Administration for a Phase 2 study of NBI-1117567, an investigational oral muscarinic M1 preferring (M1/M4) selective agonist for Alzheimer's cognition. Nxera will receive a US$10 million milestone payment from Neurocrine, expected to be recognized as revenue in Q3 FY2026. NBI-1117567 is the third compound in the muscarinic agonist portfolio to advance to Phase 2, following direclidine (NBI-1117568) in Phase 3 and NBI-1117570 in Phase 2. The collaboration agreement, signed in November 2021, grants Neurocrine development and commercialization rights to a broad portfolio of muscarinic agonists, with Nxera retaining rights for M1 agonists in Japan. Nxera is eligible for up to US$2.6 billion in milestones plus royalties.

stock
Nxera is the originator of NBI-1117567 and will receive a US$10 million milestone payment, strengthening its financial position and validating its drug discovery platform.
Importance 100.0 Sentiment 70.0
stock
Neurocrine received IND acceptance for NBI-1117567, advancing its Alzheimer's pipeline and triggering a milestone payment to Nxera.
Importance 90.0 Sentiment 60.0
govactor
The FDA accepted the IND, allowing the Phase 2 study to proceed, a key regulatory step for the drug's development.
Importance 80.0 Sentiment 0.0
cnt
The FDA's acceptance enables clinical development in the US, a major market for Alzheimer's treatments.
Importance 50.0 Sentiment 20.0
cnt
Japan is a key market where Nxera retains development and commercialization rights for M1 agonists, and the drug addresses an unmet medical need there.
Importance 40.0 Sentiment 20.0
curr
The milestone payment is denominated in US dollars, providing Nxera with foreign currency revenue.
Importance 30.0 Sentiment 0.0
per
As CEO of Nxera, Cargill commented on the milestone, highlighting the progress of the muscarinic agonist portfolio.
Importance 30.0 Sentiment 0.0
exch
Nxera is listed on the Tokyo Stock Exchange, and positive news may influence its stock price.
Importance 20.0 Sentiment 20.0
United States ally ↔ Japan The United States considers Japan a cornerstone defense ally and a vital economic partner in the Indo-Pacific, with exte
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.